Acalabrutinib (Acala) vs Idelalisib plus Rituximab (IdR) or Bendamustine plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND final results

  • Welslau, M.; 
  • Ghia, P.; 
  • Pluta, A.; 
  • Wach, M.; 
  • Lysak, D.; 
  • ... Lee, J. H.; 
  • 외 15명
Citations

WEB OF SCIENCE

0
제목
Acalabrutinib (Acala) vs Idelalisib plus Rituximab (IdR) or Bendamustine plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND final results
저자
Welslau, M.; Ghia, P.; Pluta, A.; Wach, M.; Lysak, D.; Kozak, T.; Simkovic, M.; Kaplan, P.; Kraychok, I; Illes, A.; de la Serna, J.; Dolan, S.; Campbell, P.; Musuraca, G.; Jacob, A.; Avery, E. J.; Lee, J. H.; Wang, D.; Patel, P.; Quah, C.; Jurczak, W.
발행일
2020-10
유형
Meeting Abstract
저널명
Oncology Research and Treatment
권
43
호
SUPPL 4
페이지
71 ~ 72